Novavax announced facility expansion to support global vaccine development
On Nov. 2, 2020, Novavax announced the expansion of its Maryland campus to accommodate the company’s rapid growth…
PerkinElmer received CE Mark for multi-analyte respiratory panel including COVID-19
On Oct. 26, 2020, PerkinElmer announced that its PKamp Respiratory SARS-CoV-2 RT-PCR Panel had received clearance to be…
CerTest Biotec and BD announced CE Mark for combination COVID-19, Influenza, RSV test
On Oct. 21, 2020, CerTest Biotec, along with BD (Becton, Dickinson), announced that the VIASURE SARS-CoV-2 (N1 +…
OPKO Health’s BioReference Laboratories launched multiplex COVID-19 and influenza A/B test
On Oct. 20, 2020, BioReference Laboratories, an OPKO Health company, announced that it was accepting specimens for a…
University of Oxford scientists developed extremely rapid diagnostic test for Covid-19
On Oct. 15, 2020, scientists from the University of Oxford’s Department of Physics announced they had developed an…
Biotechnology | Infectious Disease | Influenza | Measles | Plague | Polio | Vaccine
DARPA awarded Moderna $56 Million to enable small-scale, rapid mobile manufacturing of vaccines and therapeutics
On Oct. 8, 2020, Moderna announced an agreement for a commitment of up to $56 million from the…
Sonic Healthcare enhanced test offerings with launch of multiplex assay for COVID-19 and flu
On Oct. 7, 2020, Sonic Healthcare USA announced that it had launched a multiplex RT-PCR assay that combined…
HHS funded development of needle-free vaccine administration technology
On Oct. 6, 2020, the U.S. Department of Health and Human Services (HHS) announced funding of a patch…
Vaxxas announced $22 million award from U.S. Government to advance Vaxxas Needle-Free HD-MAP vaccine patch
On Oct. 5, 2020, Vaxxas announced a $22 million United States government award to support the deployment of…
Quidel received Emergency Authorization for rapid antigen ‘ABC test’ assay for Influenza A+B and COVID-19
On Oct. 2, 2020, Quidel announced that it had received Emergency Use Authorization from the U.S. Food and…
Quest Diagnostics launched three new combined COVID-19 and respiratory virus tests
On Sept. 30, 2020, Quest Diagnostics announced three different test options for healthcare providers across the U.S.to aid…
BD announced CE Mark of portable, rapid point-of-care antigen test to detect SARS-CoV-2 in 15 minutes
On Sept. 30, 2020, BD (Becton, Dickinson) announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the…
XBiotech to develop human antibody combination as candidate treatment for influenza-COVID-19 co-infection
On Sept. 21, 2020, XBiotech announced it was developing a new breakthrough candidate therapy it calls FLUVID for…
Sanofi and GSK confirmed agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine
On Sept. 18, 2020, Sanofi and GSK finalised and signed an advanced purchase agreement with the European Commission…
Biotechnology | COVID-19 | Infectious Disease | Influenza | NIH | Vaccine
Vaxess Technologies to develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with Medigen
On Sept. 15, 2020, Vaxess Technologies and Medigen Vaccine Biologics (MBV) announced a partnership to develop a combined…
Flu may increase the spread of Covid-19
On Sept. 14, 2020, scientists at the Max Planck Institute for Infection Biology in Berlin and the Institut…
The ACIP updated flu vaccine recommendations for 2020-2021
On Sept. 9, 2020, the American Academy of Family Physicians (AAFP) reviewed and agreed with the Advisory Committee…
LabCorp launched first combined test for Covid-19, flu and RSV in time for flu season
On Sept. 8, 2020, LabCorp announced the launch of the first testing method to simultaneously detect COVID-19, influenza…
DiaSorin Molecular received FDA clearance for the Simplexa Flu A/B & RSV Direct Gen II Assay
On Sept. 7, 2020, DiaSorin Molecular announced that it had received U.S. Food and Drug Administration (FDA) Clearance…
Sanofi and GSK initiated Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
On Sept. 3, 2020, Sanofi and GSK announced the start of the Phase 1/2 clinical trial for their…
Biotechnology | CDC | Infectious Disease | Influenza | NIH | Therapeutics
U.S. Government exercised option to purchase additional RAPIVAB from BioCryst for delivery to Strategic National Stockpile
On Sept. 3, 2020, BioCryst Pharmaceuticals announced that the U.S. Department of Health and Human Services (HHS) had…
Roche received FDA Emergency Use Authorization for the cobas SARS-CoV-2 & influenza A/B test for use on cobas 6800/8800 systems
On Sept. 3, 2020, Roche announced that the cobas SARS-CoV-2 & Influenza A/B Test for use on the…
Janssen discontinued Pimodivir influenza development program
On Sept. 2, 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had made a…
NIH awarded MicroGEM $409 million to fast-track rapid, no-lab COVID-19 saliva test
On Sept. 2, 2020, MicroGEM announced it had been awarded up to $40.9 million by the National Institutes…
CDC published ACIP 2020-21 influenza vaccination recommendations
On Aug. 21, 2020, the CDC published Immunization Practices Advisory Committee (ACIP) 2020-21 influenza vaccination recommendations. Routine annual…
Biotechnology | COVID-19 | Influenza | NIH
Celdara Medical announced receipt of NIH funding for pandemic influenza antiviral development
On Aug. 12, 2020, Celdara Medical announced that the NIH had awarded a Small Business Innovation Research (SBIR)…
Sanofi and GSK announced discussions with EU to supply up to 300 million doses of COVID-19 vaccine
On Jul. 31, 2020, Sanofi and GSK announced advanced discussions, with the European Commission for the supply of…
Seqirus began shipping 2020/21 influenza vaccines to U.S. market
On Jul. 30, 2020, Seqirus announced it had begun shipping its portfolio of seasonal influenza vaccines to customers…
Sanofi and GSK agreed with the UK government to supply up to 60 million doses of COVID-19 vaccine
On Jul. 29, 2020, Sanofi and GSK announced an agreement with the UK government for the supply of…
MediciNova announced SARS-CoV-2 vaccine joint development with BioComo and Mie University Japan
On Jul. 27, 2020, MediciNova announced an agreement with BioComo and Mie University (Mie prefecture, Japan) for joint…